Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures
International Journal of Clinical Pharmacy · 17.03.2026 · 48 (4) · 1412-1423
DOI: 10.1007/s11096-026-02119-x ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 17.03.2026. Verfasst von Chenning Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Approval, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Development Fund of Macau SAR, University of Macau.
Abstract (Originalsprache)
INTRODUCTION: The introduction of Accelerated Drug Marketing Registration Procedures (ADMRPs) in China has improved patient access to innovative therapies, but concerns remain about the robustness and consistency of efficacy evidence. AIM: This study aimed to compare the treatment efficacy of approved targeted therapies for non-small cell lung cancer (NSCLC) before and after the implementation of ADMRPs. METHOD: In this retrospective study, we analyzed targeted therapies for NSCLC approved in China as of December 31, 2024. Approvals were categorized as pre-policy or post-policy groups based on the July 1, 2020 implementation of ADMRPs. Descriptive statistics were used to examine approved indications and pivotal trial designs. Meta-analysis and meta-regression compared pre-approval efficacy outcomes, including overall survival (OS), progression-free survival (PFS), disease-free survival, and objective response rate (ORR), between groups. Sensitivity analyses evaluated post-marketing OS data and the robustness of results. RESULTS: A total of 59 indications supported by 72 trials were approved. Post-policy approvals increased markedly (41 vs 18), with rises in domestic drugs (16.7% pre-policy vs 61.0% post-policy) and uncommon targets (5.6% pre-policy vs 43.9% post-policy) (both P < 0.05). Pivotal trials shifted from primarily Phase III-IV randomized controlled trials (RCTs) (76.0%) pre-policy to Phase I-II single-arm designs (68.1%) post-policy, mainly supporting drugs for uncommon or resistance mutations, whereas approvals for classical targets remained predominantly based on RCTs (90.0% pre-policy vs 93.8% post-policy; P = 0.416). Meta-analyses found no significant differences in pre-approval efficacy between groups for PFS (HR: 0.52 [0.45-0.61] vs 0.44 [0.36-0.54]; P = 0.206) or ORR (0.63 [0.55-0.70] vs 0.65 [0.59-0.70]; P = 0.705). However, OS meta-analysis was only feasible in the pre-policy group, whereas OS data in the post-policy group remained immature, with a median follow-up of 17 months (IQR 8-34) after approval. CONCLUSION: After the introduction of ADMRPs, approvals of targeted therapies for NSCLC increased substantially, without significant loss of pre-approval treatment efficacy. However, due to the limited follow-up, definitive survival benefits for the post-policy group cannot yet be established. The increased reliance on single-arm trials underscores the necessity of rigorous confirmatory post-marketing studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China. chihuali@um.edu.mo.
- Centre for Pharmaceutical Regulatory Sciences, University of Macau, Macao SAR, China. chihuali@um.edu.mo.
- DPM, Faculty of Health Sciences, University of Macau, Macao SAR, China. chihuali@um.edu.mo.
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China. yuanjiahu@um.edu.mo.
- Centre for Pharmaceutical Regulatory Sciences, University of Macau, Macao SAR, China. yuanjiahu@um.edu.mo.
Förderung
- Science and Technology Development Fund of Macau SAR
- University of Macau
Zitieren
APA
Liu, C., Lyu, L., Zhang, Y., Tian, Y., Yuan, J., Li, C., & Hu, Y. (2026). Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures. International Journal of Clinical Pharmacy, 48(4), 1412-1423. https://doi.org/10.1007/s11096-026-02119-x
Vancouver
Liu C, Lyu L, Zhang Y, Tian Y, Yuan J, Li C, et al. Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures. International Journal of Clinical Pharmacy. 2026;48(4):1412-1423. doi:10.1007/s11096-026-02119-x
BibTeX
@article{Liu2026,
author = {Liu, Chenning and Lyu, Liyang and Zhang, Yufan and Tian, Yingyi and Yuan, Jing and Li, Chihua and Hu, Yuanjia},
title = {Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures},
journal = {International Journal of Clinical Pharmacy},
year = {2026},
volume = {48},
number = {4},
pages = {1412--1423},
doi = {10.1007/s11096-026-02119-x}
}
EUVIMED